Ibrutinib Treatment In Waldenström Macroglobulinemia Waldenström macroglobulinemia (WM) is a rare type of non-hogdkins lymphoma driven by the gene mutation MYD88L265P. Ibrutinib, the first approved treatment, is effective but can cause side effects. A study found that 27% of WM patients needed to reduce Ibrutinib doses due to side effects like
Tag: cancer
Stomach Cancer: A Meta-Analysis Of Robotic Surgery Complications
Stomach Cancer: A Meta-Analysis Of Robotic Surgery Complications Gastric or stomach cancer prevalence varies significantly around the world, with higher rates in Asia, Africa, South America, and Eastern Europe. However, in the United States, stomach cancer is a growing concern due to its increased occurrence in the elderly population and its
Chemotherapy-Induced Thrombocytopenia in Nasopharyngeal Carcinoma
Chemotherapy-Induced Thrombocytopenia in Nasopharyngeal Carcinoma Overview This study aimed to investigate serious chemotherapy-induced thrombocytopenia (CIT) in nasopharyngeal carcinoma (NPC), focusing on its incidence, consequences, and predictors. The retrospective analysis of NPC patients from 2013 to 2015 revealed a 5.21% incidence of serious chemotherapy-induced thrombocytopenia. Patients experiencing severe thrombocytopenia had notably worse long-term prognoses,
Postoperative Delirium In The NICU: Hormonal Risk Factors
Postoperative Delirium In The NICU: Hormonal Risk Factors In neurosurgery, pituitary adenoma ranks as the second most common brain tumor. Recent advances in endoscope-assisted transsphenoidal surgery have revolutionized tumor resection, reducing complications. However, postoperative complications, particularly endocrine-related issues, remain critical in neurosurgical intensive care units (NICUs). Notably, postoperative delirium, intricately linked
Cancer Care: Gender Bias In Decision-Making
Cancer Care: Gender Bias In Decision-Making Overview In the realm of cancer care, the integration and execution of shared decision-making within clinical practice guidelines (CPGs) and consensus statements could potentially exhibit gender-based disparities. This study aimed to meticulously analyze recommendations pertaining to shared decision-making within CPGs and consensus statements, specifically focusing on
Non-Hodgkin Lymphoma Survivors: Secondary Malignancy Risk
Non-Hodgkin Lymphoma Survivors: Secondary Malignancy Risk The number of non-Hodgkin lymphoma (NHL) cases is rising, with an estimated 81,560 new diagnoses in the US in 2021. As survival rates improve, more NHL survivors face potential late effects, including secondary malignancies (SM) linked to treatments like chemotherapy and radiation. This research revisits
Eosinophilic Dermatosis In Hematological Malignancy (EDHM): Case Study Reports
Eosinophilic Dermatosis In Malignancy (EDHM): Case Study Reports Overview Patients with hematological malignancies may develop various skin eruptions, and one such condition is eosinophilic dermatosis of hematological malignancy (EDHM), also known as an 'insect bite-like' reaction. While cutaneous reactions are not uncommon in hematological malignancies, EDHM is a relatively rare condition that
Uterine Leiomyosarcoma: A Meta-Analysis Of Systemic Therapy Effectiveness
Uterine Leiomyosarcoma: Systemic Therapy Effectiveness Overview Uterine leiomyosarcoma (uLMS) is an aggressive type of mesenchymal tumor linked to a bleak prognosis. The primary treatment for advanced uLMS is systemic chemotherapy, although the most effective regimen remains uncertain. To address this, we conducted an extensive analysis, including both meta-analysis and metaregression, aiming to
Massage Therapy For Oncology Patient Pain
Massage Therapy For Oncology Patient Pain Overview This study aimed to investigate the impact of massage therapy (MT) as a nonpharmacologic approach for addressing various symptoms experienced by children, adolescents, and young adults with hematologic and/or oncologic conditions. The researchers focused on two patient groups: those with sickle cell disease (SCD) and
Eyelid Rhabdomyosarcoma Survival In Children’s Oncology
Eyelid Rhabdomyosarcoma Survival In Children's Oncology Overview Survival outcomes in Orbital Rhabdomyosarcoma (ORMS) typically show excellent results, especially in low-risk cases (stage 1, group I-III, embryonal RMS). However, long-term follow-up data on low-risk ORMS and less common subgroups treated in recent Children's Oncology Group (COG) trials were previously unreported. To fill this
